Clinical Outcomes of Stereotactic Body Radiotherapy for Early-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Study

Background Small-cell lung cancer (SCLC) is an aggressive malignancy with early metastatic potential. Although surgery plus chemotherapy is standard for early-stage disease, many patients are not surgical candidates. Stereotactic body radiotherapy (SBRT) has emerged as a potential alternative in this setting. We report single-institution outcomes and toxicity of SBRT in early-stage SCLC. Methodology We retrospectively reviewed patients with histologically confirmed T1-T2N0 SCLC treated with curative-intent SBRT, regardless of fractionation, between 2018 and 2023. The primary endpoint was locoregional control (LRC); secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. Survival was analyzed using Kaplan-Meier estimates and log-rank tests; LRC was estimated using cumulative incidence, with death as a competing event. Results In total, 12 patients were included, with a median age of 76.5 years; nine (75.0%) were male, nine (75.0%) had peripheral tumors, and seven (58.3%) received chemotherapy. At a median follow-up of 20.6 months, median OS was 48.2 months (95% confidence interval (CI): 6.0-90.5), median PFS was 19.0 months (95% CI: 0.0-42.8), and median LRC was not reached, with a two-year LRC rate of 80%. Distant metastases occurred in seven (58.3%) patients and locoregional recurrence in three (25.0%), and no grade ≥2 toxicities were observed. In exploratory subgroup analyses, survival was numerically longer with chemotherapy (p = 0.281), peripheral tumors (p = 0.066), ECOG performance status 0-1 (p = 0.284), and tumors <3 cm (p = 0.350), although none of these differences were statistically significant. Conclusions In this small retrospective cohort, SBRT was feasible and was associated with encouraging locoregional control and no documented grade ≥2 toxicity in patients with medically inoperable early-stage SCLC. These preliminary, hypothesis-generating findings warrant validation in multicenter collaborative studies and prospective registries.

Authors

Publication Details

Journal
Cureus
Published
2026-11-21
DOI
https://doi.org/10.7759/cureus.120032
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical Outcomes of Stereotactic Body Radiotherapy for Early-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Study

Joana Cardia, Isabel Rodrigues, João Basílio, Susana Costa et al.
Cureus
Lung Cancer Research Studies
article

Clinical Outcomes of Stereotactic Body Radiotherapy for Early-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Study

Joana Cardia, Isabel Rodrigues, João Basílio, Susana Costa, Tiago Figueiredo, João Lima
article en

Abstract

Background Small-cell lung cancer (SCLC) is an aggressive malignancy with early metastatic potential. Although surgery plus chemotherapy is standard for early-stage disease, many patients are not surgical candidates. Stereotactic body radiotherapy (SBRT) has emerged as a potential alternative in this setting. We report single-institution outcomes and toxicity of SBRT in early-stage SCLC. Methodology We retrospectively reviewed patients with histologically confirmed T1-T2N0 SCLC treated with curative-intent SBRT, regardless of fractionation, between 2018 and 2023. The primary endpoint was locoregional control (LRC); secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. Survival was analyzed using Kaplan-Meier estimates and log-rank tests; LRC was estimated using cumulative incidence, with death as a competing event. Results In total, 12 patients were included, with a median age of 76.5 years; nine (75.0%) were male, nine (75.0%) had peripheral tumors, and seven (58.3%) received chemotherapy. At a median follow-up of 20.6 months, median OS was 48.2 months (95% confidence interval (CI): 6.0-90.5), median PFS was 19.0 months (95% CI: 0.0-42.8), and median LRC was not reached, with a two-year LRC rate of 80%. Distant metastases occurred in seven (58.3%) patients and locoregional recurrence in three (25.0%), and no grade ≥2 toxicities were observed. In exploratory subgroup analyses, survival was numerically longer with chemotherapy (p = 0.281), peripheral tumors (p = 0.066), ECOG performance status 0-1 (p = 0.284), and tumors <3 cm (p = 0.350), although none of these differences were statistically significant. Conclusions In this small retrospective cohort, SBRT was feasible and was associated with encouraging locoregional control and no documented grade ≥2 toxicity in patients with medically inoperable early-stage SCLC. These preliminary, hypothesis-generating findings warrant validation in multicenter collaborative studies and prospective registries.

Cureus
Lung Cancer Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Clinical Outcomes of Stereotactic Body Radiotherapy for Early-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Study — Joana Cardia, Isabel Rodrigues, et al. · Cureus (2026) | TGRS Research Map | TGRS